SSP

Item 4 of the Original Schedule 13D is hereby amended to add the following: On March 11, 2026, in accordance with the Scripps Family Agreement, the Reporting Persons held a meeting to, among other things, determine how the Common Voting Shares held by the Reporting Persons would be voted with respect to each proposal at the Company's 2026 annual meeting of shareholders. At such meeting, the Reporting Persons voted in favor of the ratification of the Rights Plan, as further described in the preliminary proxy statement filed by the Company on March 9, 2026 (the "Preliminary Proxy"). If the Rights Plan is not ratified at the Company's 2026 annual meeting, the Rights Plan would expire on the date of such meeting. If the Rights Plan is ratified at the Company's 2026 annual meeting, the Rights Plan would expire on the earlier of (i) November 26, 2026, or (ii) the date on which the rights are redeemed or exchanged by the Board in accordance with the Rights Agreement. In addition, the Reporting Persons also voted in favor of the other matters being submitted by the Company to the shareholders at the 2026 annual meeting, including the election of directors, in each case as further described in the Preliminary Proxy. Therefore, in accordance with the Scripps Family Agreement, the Reporting Persons plan to vote all their Common Voting Shares in favor of each such proposal at the Company's 2026 annual meeting. Since the filing of the Original Schedule 13D, the Reporting Persons have engaged in transactions in the Common Shares, including those set forth on Appendix C hereto. These transactions have included and may in the future include open market purchases, open market sales, gifts, director equity award grants and vesting, conversions, contributions to trusts and distributions from trusts and other transfers for estate planning, private investment, liquidity or charitable purposes. Without limiting the foregoing, on March 11, 2026, Charles Barmonde, a Reporting Person serving as a director on the board of directors of the Company, entered into a written trading plan with Merrill Lynch, Pierce, Fenner & Smith (the "Broker") in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Rule 10b5-1 Plan"). Under the Rule 10b5-1 Plan, Mr. Barmonde may sell up to an aggregate of 40,000 Class A Common Shares if certain price targets are reached during the term of the Rule 10b5-1 Plan, which commences on September 8, 2026, and ends on September 8, 2027. All sales under the Rule 10b5-1 Plan will be made in the discretion of the Broker, subject to certain market conditions and the other terms and conditions set forth in the Rule 10b5-1 Plan.

Item 4 of the Original Schedule 13D is hereby amended to add the following: On March 11, 2026, in accordance with the Scripps Family Agreement, the Reporting Persons held a meeting to, among other things, determine how the Common Voting Shares held by the Reporting Persons would be voted with respect to each proposal at the Company's 2026 annual meeting of shareholders. At such meeting, the Reporting Persons voted in favor of the ratification of the Rights Plan, as further described in the preliminary proxy statement filed by the Company on March 9, 2026 (the "Preliminary Proxy"). If the Rights Plan is not ratified at the Company's 2026 annual meeting, the Rights Plan would expire on the date of such meeting. If the Rights Plan is ratified at the Company's 2026 annual meeting, the Rights Plan would expire on the earlier of (i) November 26, 2026, or (ii) the date on which the rights are redeemed or exchanged by the Board in accordance with the Rights Agreement. In addition, the Reporting Persons also voted in favor of the other matters being submitted by the Company to the shareholders at the 2026 annual meeting, including the election of directors, in each case as further described in the Preliminary Proxy. Therefore, in accordance with the Scripps Family Agreement, the Reporting Persons plan to vote all their Common Voting Shares in favor of each such proposal at the Company's 2026 annual meeting. Since the filing of the Original Schedule 13D, the Reporting Persons have engaged in transactions in the Common Shares, including those set forth on Appendix C hereto. These transactions have included and may in the future include open market purchases, open market sales, gifts, director equity award grants and vesting, conversions, contributions to trusts and distributions from trusts and other transfers for estate planning, private investment, liquidity or charitable purposes. Without limiting the foregoing, on March 11, 2026, Charles Barmonde, a Reporting Person serving as a director on the board of directors of the Company, entered into a written trading plan with Merrill Lynch, Pierce, Fenner & Smith (the "Broker") in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Rule 10b5-1 Plan"). Under the Rule 10b5-1 Plan, Mr. Barmonde may sell up to an aggregate of 40,000 Class A Common Shares if certain price targets are reached during the term of the Rule 10b5-1 Plan, which commences on September 8, 2026, and ends on September 8, 2027. All sales under the Rule 10b5-1 Plan will be made in the discretion of the Broker, subject to certain market conditions and the other terms and conditions set forth in the Rule 10b5-1 Plan.

Item 4 of the Original Schedule 13D is hereby amended to add the following: On March 11, 2026, in accordance with the Scripps Family Agreement, the Reporting Persons held a meeting to, among other things, determine how the Common Voting Shares held by the Reporting Persons would be voted with respect to each proposal at the Company's 2026 annual meeting of shareholders. At such meeting, the Reporting Persons voted in favor of the ratification of the Rights Plan, as further described in the preliminary proxy statement filed by the Company on March 9, 2026 (the "Preliminary Proxy"). If the Rights Plan is not ratified at the Company's 2026 annual meeting, the Rights Plan would expire on the date of such meeting. If the Rights Plan is ratified at the Company's 2026 annual meeting, the Rights Plan would expire on the earlier of (i) November 26, 2026, or (ii) the date on which the rights are redeemed or exchanged by the Board in accordance with the Rights Agreement. In addition, the Reporting Persons also voted in favor of the other matters being submitted by the Company to the shareholders at the 2026 annual meeting, including the election of directors, in each case as further described in the Preliminary Proxy. Therefore, in accordance with the Scripps Family Agreement, the Reporting Persons plan to vote all their Common Voting Shares in favor of each such proposal at the Company's 2026 annual meeting. Since the filing of the Original Schedule 13D, the Reporting Persons have engaged in transactions in the Common Shares, including those set forth on Appendix C hereto. These transactions have included and may in the future include open market purchases, open market sales, gifts, director equity award grants and vesting, conversions, contributions to trusts and distributions from trusts and other transfers for estate planning, private investment, liquidity or charitable purposes. Without limiting the foregoing, on March 11, 2026, Charles Barmonde, a Reporting Person serving as a director on the board of directors of the Company, entered into a written trading plan with Merrill Lynch, Pierce, Fenner & Smith (the "Broker") in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Rule 10b5-1 Plan"). Under the Rule 10b5-1 Plan, Mr. Barmonde may sell up to an aggregate of 40,000 Class A Common Shares if certain price targets are reached during the term of the Rule 10b5-1 Plan, which commences on September 8, 2026, and ends on September 8, 2027. All sales under the Rule 10b5-1 Plan will be made in the discretion of the Broker, subject to certain market conditions and the other terms and conditions set forth in the Rule 10b5-1 Plan.

Item 4 of the Original Schedule 13D is hereby amended to add the following: On March 11, 2026, in accordance with the Scripps Family Agreement, the Reporting Persons held a meeting to, among other things, determine how the Common Voting Shares held by the Reporting Persons would be voted with respect to each proposal at the Company's 2026 annual meeting of shareholders. At such meeting, the Reporting Persons voted in favor of the ratification of the Rights Plan, as further described in the preliminary proxy statement filed by the Company on March 9, 2026 (the "Preliminary Proxy"). If the Rights Plan is not ratified at the Company's 2026 annual meeting, the Rights Plan would expire on the date of such meeting. If the Rights Plan is ratified at the Company's 2026 annual meeting, the Rights Plan would expire on the earlier of (i) November 26, 2026, or (ii) the date on which the rights are redeemed or exchanged by the Board in accordance with the Rights Agreement. In addition, the Reporting Persons also voted in favor of the other matters being submitted by the Company to the shareholders at the 2026 annual meeting, including the election of directors, in each case as further described in the Preliminary Proxy. Therefore, in accordance with the Scripps Family Agreement, the Reporting Persons plan to vote all their Common Voting Shares in favor of each such proposal at the Company's 2026 annual meeting. Since the filing of the Original Schedule 13D, the Reporting Persons have engaged in transactions in the Common Shares, including those set forth on Appendix C hereto. These transactions have included and may in the future include open market purchases, open market sales, gifts, director equity award grants and vesting, conversions, contributions to trusts and distributions from trusts and other transfers for estate planning, private investment, liquidity or charitable purposes. Without limiting the foregoing, on March 11, 2026, Charles Barmonde, a Reporting Person serving as a director on the board of directors of the Company, entered into a written trading plan with Merrill Lynch, Pierce, Fenner & Smith (the "Broker") in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Rule 10b5-1 Plan"). Under the Rule 10b5-1 Plan, Mr. Barmonde may sell up to an aggregate of 40,000 Class A Common Shares if certain price targets are reached during the term of the Rule 10b5-1 Plan, which commences on September 8, 2026, and ends on September 8, 2027. All sales under the Rule 10b5-1 Plan will be made in the discretion of the Broker, subject to certain market conditions and the other terms and conditions set forth in the Rule 10b5-1 Plan.

Item 4 of the Original Schedule 13D is hereby amended to add the following: On March 11, 2026, in accordance with the Scripps Family Agreement, the Reporting Persons held a meeting to, among other things, determine how the Common Voting Shares held by the Reporting Persons would be voted with respect to each proposal at the Company's 2026 annual meeting of shareholders. At such meeting, the Reporting Persons voted in favor of the ratification of the Rights Plan, as further described in the preliminary proxy statement filed by the Company on March 9, 2026 (the "Preliminary Proxy"). If the Rights Plan is not ratified at the Company's 2026 annual meeting, the Rights Plan would expire on the date of such meeting. If the Rights Plan is ratified at the Company's 2026 annual meeting, the Rights Plan would expire on the earlier of (i) November 26, 2026, or (ii) the date on which the rights are redeemed or exchanged by the Board in accordance with the Rights Agreement. In addition, the Reporting Persons also voted in favor of the other matters being submitted by the Company to the shareholders at the 2026 annual meeting, including the election of directors, in each case as further described in the Preliminary Proxy. Therefore, in accordance with the Scripps Family Agreement, the Reporting Persons plan to vote all their Common Voting Shares in favor of each such proposal at the Company's 2026 annual meeting. Since the filing of the Original Schedule 13D, the Reporting Persons have engaged in transactions in the Common Shares, including those set forth on Appendix C hereto. These transactions have included and may in the future include open market purchases, open market sales, gifts, director equity award grants and vesting, conversions, contributions to trusts and distributions from trusts and other transfers for estate planning, private investment, liquidity or charitable purposes. Without limiting the foregoing, on March 11, 2026, Charles Barmonde, a Reporting Person serving as a director on the board of directors of the Company, entered into a written trading plan with Merrill Lynch, Pierce, Fenner & Smith (the "Broker") in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Rule 10b5-1 Plan"). Under the Rule 10b5-1 Plan, Mr. Barmonde may sell up to an aggregate of 40,000 Class A Common Shares if certain price targets are reached during the term of the Rule 10b5-1 Plan, which commences on September 8, 2026, and ends on September 8, 2027. All sales under the Rule 10b5-1 Plan will be made in the discretion of the Broker, subject to certain market conditions and the other terms and conditions set forth in the Rule 10b5-1 Plan.

Item 4 of the Original Schedule 13D is hereby amended to add the following: On March 11, 2026, in accordance with the Scripps Family Agreement, the Reporting Persons held a meeting to, among other things, determine how the Common Voting Shares held by the Reporting Persons would be voted with respect to each proposal at the Company's 2026 annual meeting of shareholders. At such meeting, the Reporting Persons voted in favor of the ratification of the Rights Plan, as further described in the preliminary proxy statement filed by the Company on March 9, 2026 (the "Preliminary Proxy"). If the Rights Plan is not ratified at the Company's 2026 annual meeting, the Rights Plan would expire on the date of such meeting. If the Rights Plan is ratified at the Company's 2026 annual meeting, the Rights Plan would expire on the earlier of (i) November 26, 2026, or (ii) the date on which the rights are redeemed or exchanged by the Board in accordance with the Rights Agreement. In addition, the Reporting Persons also voted in favor of the other matters being submitted by the Company to the shareholders at the 2026 annual meeting, including the election of directors, in each case as further described in the Preliminary Proxy. Therefore, in accordance with the Scripps Family Agreement, the Reporting Persons plan to vote all their Common Voting Shares in favor of each such proposal at the Company's 2026 annual meeting. Since the filing of the Original Schedule 13D, the Reporting Persons have engaged in transactions in the Common Shares, including those set forth on Appendix C hereto. These transactions have included and may in the future include open market purchases, open market sales, gifts, director equity award grants and vesting, conversions, contributions to trusts and distributions from trusts and other transfers for estate planning, private investment, liquidity or charitable purposes. Without limiting the foregoing, on March 11, 2026, Charles Barmonde, a Reporting Person serving as a director on the board of directors of the Company, entered into a written trading plan with Merrill Lynch, Pierce, Fenner & Smith (the "Broker") in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Rule 10b5-1 Plan"). Under the Rule 10b5-1 Plan, Mr. Barmonde may sell up to an aggregate of 40,000 Class A Common Shares if certain price targets are reached during the term of the Rule 10b5-1 Plan, which commences on September 8, 2026, and ends on September 8, 2027. All sales under the Rule 10b5-1 Plan will be made in the discretion of the Broker, subject to certain market conditions and the other terms and conditions set forth in the Rule 10b5-1 Plan.

Item 4 of the Original Schedule 13D is hereby amended to add the following: On March 11, 2026, in accordance with the Scripps Family Agreement, the Reporting Persons held a meeting to, among other things, determine how the Common Voting Shares held by the Reporting Persons would be voted with respect to each proposal at the Company's 2026 annual meeting of shareholders. At such meeting, the Reporting Persons voted in favor of the ratification of the Rights Plan, as further described in the preliminary proxy statement filed by the Company on March 9, 2026 (the "Preliminary Proxy"). If the Rights Plan is not ratified at the Company's 2026 annual meeting, the Rights Plan would expire on the date of such meeting. If the Rights Plan is ratified at the Company's 2026 annual meeting, the Rights Plan would expire on the earlier of (i) November 26, 2026, or (ii) the date on which the rights are redeemed or exchanged by the Board in accordance with the Rights Agreement. In addition, the Reporting Persons also voted in favor of the other matters being submitted by the Company to the shareholders at the 2026 annual meeting, including the election of directors, in each case as further described in the Preliminary Proxy. Therefore, in accordance with the Scripps Family Agreement, the Reporting Persons plan to vote all their Common Voting Shares in favor of each such proposal at the Company's 2026 annual meeting. Since the filing of the Original Schedule 13D, the Reporting Persons have engaged in transactions in the Common Shares, including those set forth on Appendix C hereto. These transactions have included and may in the future include open market purchases, open market sales, gifts, director equity award grants and vesting, conversions, contributions to trusts and distributions from trusts and other transfers for estate planning, private investment, liquidity or charitable purposes. Without limiting the foregoing, on March 11, 2026, Charles Barmonde, a Reporting Person serving as a director on the board of directors of the Company, entered into a written trading plan with Merrill Lynch, Pierce, Fenner & Smith (the "Broker") in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Rule 10b5-1 Plan"). Under the Rule 10b5-1 Plan, Mr. Barmonde may sell up to an aggregate of 40,000 Class A Common Shares if certain price targets are reached during the term of the Rule 10b5-1 Plan, which commences on September 8, 2026, and ends on September 8, 2027. All sales under the Rule 10b5-1 Plan will be made in the discretion of the Broker, subject to certain market conditions and the other terms and conditions set forth in the Rule 10b5-1 Plan.

Item 4 of the Original Schedule 13D is hereby amended to add the following: On March 11, 2026, in accordance with the Scripps Family Agreement, the Reporting Persons held a meeting to, among other things, determine how the Common Voting Shares held by the Reporting Persons would be voted with respect to each proposal at the Company's 2026 annual meeting of shareholders. At such meeting, the Reporting Persons voted in favor of the ratification of the Rights Plan, as further described in the preliminary proxy statement filed by the Company on March 9, 2026 (the "Preliminary Proxy"). If the Rights Plan is not ratified at the Company's 2026 annual meeting, the Rights Plan would expire on the date of such meeting. If the Rights Plan is ratified at the Company's 2026 annual meeting, the Rights Plan would expire on the earlier of (i) November 26, 2026, or (ii) the date on which the rights are redeemed or exchanged by the Board in accordance with the Rights Agreement. In addition, the Reporting Persons also voted in favor of the other matters being submitted by the Company to the shareholders at the 2026 annual meeting, including the election of directors, in each case as further described in the Preliminary Proxy. Therefore, in accordance with the Scripps Family Agreement, the Reporting Persons plan to vote all their Common Voting Shares in favor of each such proposal at the Company's 2026 annual meeting. Since the filing of the Original Schedule 13D, the Reporting Persons have engaged in transactions in the Common Shares, including those set forth on Appendix C hereto. These transactions have included and may in the future include open market purchases, open market sales, gifts, director equity award grants and vesting, conversions, contributions to trusts and distributions from trusts and other transfers for estate planning, private investment, liquidity or charitable purposes. Without limiting the foregoing, on March 11, 2026, Charles Barmonde, a Reporting Person serving as a director on the board of directors of the Company, entered into a written trading plan with Merrill Lynch, Pierce, Fenner & Smith (the "Broker") in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Rule 10b5-1 Plan"). Under the Rule 10b5-1 Plan, Mr. Barmonde may sell up to an aggregate of 40,000 Class A Common Shares if certain price targets are reached during the term of the Rule 10b5-1 Plan, which commences on September 8, 2026, and ends on September 8, 2027. All sales under the Rule 10b5-1 Plan will be made in the discretion of the Broker, subject to certain market conditions and the other terms and conditions set forth in the Rule 10b5-1 Plan.